They reported slightly higher levels of carnitine in samples from high-grade gliomas compared with low-grade gliomas (a ratio of 4.21) and in the IDH wildtype compared with the IDH mutant (fold change of 3.91). This evidence concerns the gene IDH2 and central nervous system cancer.